Zamerovimab  (Synonyms: CTB011; SYN023)

Zamerovimab (CTB011; SYN023) is a mixture of human monoclonal antibodies consisting of CTB011 and CTB012. Zamerovimab binds to non-overlapping epitopes on rabies virus (RABV) glycoprotein, where CTB011 binds to antigenic site III. Zamerovimab can be used in rabies studies^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Humanized

Zamerovimab (CTB011; SYN023) (0.001-100 μg/mL, 4 h) 在 CVS 感染的 BSR 细胞中，以剂量依赖性方式诱导细胞毒性，促进病毒清除，也表明细胞毒性与表达 G 蛋白的细胞特异性相关，而这些细胞被 CTB011 靶向^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Zamerovimab (CTB011; SYN023) (0.03-1.0 mg/kg，右腓肠肌注射，一次，35 天) 可以以剂量依赖性方式增加感染了狂犬病病毒RABV BD06 的叙利亚仓鼠的存活率，在剂量分别为 0.03、0.1、0.3、1.0 mg/kg 时，存活率分别为 58%，83%，100% 和 100%^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2419087-87-7

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. Tzu-Yuan Chao, et al. SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies. PLoS Negl Trop Dis. 2017 Dec 20;11(12):e0006133.  [Content Brief]